4,901 trials
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) (AUC0-tz) — 2225.20; 2563.65…
Renal Insufficiency · Healthy
Primary: Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 3347.73; 2590.32…
Healthy
Primary: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to 119 Hours — 2073.40; 933.44 nanomole (nmol)*h/Litre (L)
Healthy
Primary: Dose Normalized Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) — 118.27; 161.69…
Hepatic Insufficiency
Primary: Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2913.55; 2837.74…
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With Drug-related Adverse Events (AEs) On-treatment — 90.0; 60.0 Percentage of participants
Healthy
Primary: Number of Participants With Drug-related Adverse Events — 0; 0; 0 Participants
Healthy
Primary: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 4164.32; 4057.42…
Healthy
Primary: The Maximum Mean Difference Between Each Single Dose of Either a Low Dose or a High Dose of Nerandomilast and Placebo in QTcF Changes From Baseline Between 20 Min to 24…
Healthy
Primary: Number of Subjects With Drug-related Adverse Events (AEs) — 1; 1; 2; 4 Participants
Healthy
Primary: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 1780; 3680 Nanomol*Hour/Liter
Healthy
Primary: Percentage of the Amount of [14C]-Radioactivity Excreted Among the Administered Single Oral Dose of [14-C] BI 1015550-EQ in Urine (Feurine, 0-tz), Faeces (Fefaeces…
Astrocytoma, Grade III · Glioblastoma
Primary: Maximum Tolerated Dose (MTD) — 150; 150 mg
Healthy Participants
Primary: Area Under the Plasma Concentration-time Curve From Time 0 to t (AUC[0-t]) for Minzasolmin — 5612; 5710; 6140 hour*nanograms per milliliter (h*ng/mL)
Primary Progressive Aphasia · Behavioral Variant of Frontotemporal Dementia · Frontotemporal Dementia, Behavioral Variant
Primary: Proportion of PPA Subjects That Showed Elevated Tau PET Binding Compared to Normal Controls — 3; 0; 17; 0 Participants